Australia News Beep
  • News Beep
  • Australia
  • Headlines
  • Business
  • Entertainment
  • Health
  • Science
  • Sports
  • Technology
Australia News Beep
Australia News Beep
  • News Beep
  • Australia
  • Headlines
  • Business
  • Entertainment
  • Health
  • Science
  • Sports
  • Technology

Browsing Tag

The Company

14 posts
HHealthcare
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Read More

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

  • March 16, 2026
Tonix Pharmaceuticals Holding Corp. TONMYA™ (cyclobenzaprine HCl sublingual tablets) launched November 17, 2025, for the treatment of fibromyalgia;…
HHealthcare
BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
Read More

BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI®

  • January 7, 2026
BioXcel Therapeutics Company remains focused on potential approval and launch of IGALMI® for the acute treatment of agitation…
MMedication
ACCESS Newswire
Read More

Amphastar Announces FDA Approval for Teriparatide Injection

  • December 15, 2025
RANCHO CUCAMONGA, CA / ACCESS Newswire / December 15, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the…
HHealthcare
BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
Read More

BioXcel Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on Late-Stage Clinical Programs for Agitation in Bipolar, Schizophrenia, and Alzheimer’s Disease

  • November 12, 2025
BioXcel Therapeutics sNDA submission expected in early Q1 2026 for expanded usage of IGALMI® in home setting based…
CComputing
D-Wave Quantum (QBTS) Announces First-Ever Qubits Japan 2025 Quantum Computing User Conference
Read More

D-Wave Quantum (QBTS) Announces First-Ever Qubits Japan 2025 Quantum Computing User Conference

  • September 18, 2025
LOS ANGELES, CA – September 17, 2025 (NEWMEDIAWIRE) – D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave” or “The Company”),…
IInternet
Kinetic Wins State Approvals of $156 Million in BEAD Grants to Expand Multi-Gig Fiber Broadband
Read More

Kinetic Wins State Approvals of $156 Million in BEAD Grants to Expand Multi-Gig Fiber Broadband

  • September 13, 2025
Almost 52,000 rural homes and businesses in four states will get access to fiber connections LITTLE ROCK, Ark.,…
HHealthcare
BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
Read More

BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia

  • September 10, 2025
BioXcel Therapeutics BXCL501 demonstrated a significant mean reduction in mCGI-S score from baseline compared to placebo at 2…
HHealthcare
BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
Read More

BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®

  • August 30, 2025
BioXcel Therapeutics BXCL501 achieved SERENITY At-Home’s primary endpoint of being well tolerated in the at-home treatment of agitation…
HHealthcare
BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
Read More

BioXcel Therapeutics To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia on August 27, 2025

  • August 26, 2025
BioXcel Therapeutics Company to host conference call at 8 a.m. ET, August 27, 2025 NEW HAVEN, Conn., Aug.…
HHealthcare
BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
Read More

BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

  • August 22, 2025
BioXcel Therapeutics Data from more than 2,600 agitation episodes collected Topline data readout is on track for August        …
CComputing
Quantum Computing Inc. Reports Second Quarter 2025 Financial Results
Read More

Quantum Computing Inc. Reports Second Quarter 2025 Financial Results

  • August 14, 2025
HOBOKEN, N.J., Aug. 14, 2025 /PRNewswire/ — Quantum Computing Inc. (“QCi” or the “Company”) (Nasdaq: QUBT), an innovative, integrated…
CComputing
Rigetti Computing Reports Second Quarter 2025 Financial Results; Announces General Availability of its 36-Qubit Multi-Chip Quantum Computer
Read More

Rigetti Computing Reports Second Quarter 2025 Financial Results; Announces General Availability of its 36-Qubit Multi-Chip Quantum Computer

  • August 13, 2025
Rigetti Computing, Inc. Cepheus-1-36Q Rigetti’s Cepheus-1-36Q modular processor. Photo credit: Drew Bird Photography Cepheus-1-36Q processor assembly A single…
Australia News Beep
www.newsbeep.com